Peanut Allergy Market

Global Peanut Allergy Market expected to hit USD 40.84 Bn by 2030 from USD 0.22 Bn in 2023 at a CAGR of 110% during the forecast period

Peanut Allergy Market Overview

Peanut Allergy is considered one of the most common causes of allergy attacks, which sometimes can be life-threatening. The peanut allergy is expected to occur through direct contact, cross-contact and inhalation of dust and aerosols containing peanuts. Children and adults are most exposed to the peanut allergy. The growing concerns regarding allergies in this age group are expected to drive the Peanut Allergy Market.To know about the Research Methodology :- Request Free Sample Report

Peanut Allergy Market Dynamics

Market Drivers

The growing rate of peanut allergy in the children and geriatric population is expected to drive the Peanut Allergy Market. It becomes a major concern for families across the world since the MMR study reports that approximately 2 percent of the population is affected and allergy depends on how much peanut protein was consumed during infancy. The Learning Early about Peanut Allergy (LEAP) study tries to minimize peanut allergies in children by introducing peanuts to infants.

The Peanut Allergy Market is also driven by carrying out a peanut allergy action plan for specific symptoms, if symptoms are mild such as swelling then Benadryl or Zyrtec is used and if symptoms are serious such as trouble breathing, wheezing, throat swelling, vomiting, diarrhea, dizziness then epinephrine must be used.

The Continuous increase in cases of peanut allergies all over the world is creating a lucrative opportunity for Peanut Allergy Key Players in the global Peanut Allergy Industry. Also, the continuous investment by Peanut Allergy Key Companies in research and development to launch new medicines for Peanut Allergy Treatments is expected to boost the Peanut Allergy Market. Allergen Research Corporation (ARC) now known as Aimmune Therapeutics has raised USD 80 million to tackle the problem of peanut allergies through their research. This is expected to drive the Peanut Allergy Market. The company is working on developing a product that desensitizes patients so that accidental exposure to peanuts doesn't cause a severe allergic response.

Peanut Allergy Market Trends

Epicutaneous peanut immunotherapy: Epicutaneous peanut immunotherapy is a patch that delivers peanut protein into the skin but has to stay on for up to 24 hours a day. Epicutaneous peanut immunotherapy (EPIT) is promising the treatment of peanut allergy in children and young adults, which avoids life-threatening allergic reactions. The efficacy of this treatment increased to 51.8 percent and is expected to drive the Peanut Allergy Market. Epicutaneous peanut immunotherapy lowers the risk of allergic reactions and is easy to use.

Oral peanut immunotherapy: Oral immunotherapy with peanut protein has been performed for decades in selected patients at allergy centers including both low and higher doses of peanut protein. The efficacy of oral peanut immunotherapy is high and most of the patients achieved desensitization. This is propelling the growth of the Peanut Allergy Market. The OIT helps desensitize patients to the food they are allergic to by giving them small quantities of the food allergen to ingest every day and gradually building their body’s resistance to the allergic food.

Sublingual peanut immunotherapy: Sublingual peanut immunotherapy refers to repeatedly exposing patients to small doses of allergen to make them less sensitive to it. This repeated exposure to small but increasing doses of allergen desensitizes patients’ immune systems and the body becomes tolerant of the allergen and cures the allergy of a patient. This is a popular form of therapy for Peanut Allergy Treatment and is expected to grow significantly in the Peanut Allergy Market.

Use of biologics to treat peanut allergy: The biological agent that has been the longest in use in the field of allergies is anti-IgE, which has been approved for the treatment of allergies. Peanut allergy continues to pose problems due to its increased frequency and its increasingly high severity. These multiple types of immunotherapies are expected to drive the Peanut Allergy Market.

Market Restraints

The report has used primary and secondary research methods to collect the Peanut Allergy Industry Data and analyses that data through SWOT analysis and PORTER’s five force model, which includes Peanut Allergy Market Growth drivers, opportunities, restraints and regional insights. The high price associated with the drugs for Peanut Allergy Treatment is expected to hamper the growth of the Peanut Allergy Market. Also, the lack of awareness regarding allergies to such small ingredients and the treatments such as oral immunotherapy is expected to reduce the severity of allergy but needs a lengthy intervention with no known standardized methodology, which is expected to impede the growth of the Peanut Allergy Market.

Regional Insights

North America held the largest share of the Peanut Allergy Market in 2023 since peanut allergy is one of the eight most common food allergies that affects nearly 2 percent of the United States population. Canada is also one of the North American countries with the highest prevalence of peanut allergies. The continuous research and developments in the Peanut Allergy Industry by major Peanut Allergy Key Players has been driving the regions market growth. One of the major reason that North Americans allergic to peanuts is due to their genetics. The region is emerged as a lucrative opportunity for Peanut Allergy Key Companies to increase their Peanut Allergy Market Share.

After North America, Europe is expected to grow at the highest rate during the forecast period (2024-2030) in Peanut Allergy Market. Recently, on January 5, 2021, European Commission approved PALFORZIA for the treatment of peanut allergy. PALFORZIA is a complex biologic drug used with a structured dosing approach that builds on a century of oral immunotherapy (OIT) research. With OIT, the specific allergenic proteins are ingested initially in very small quantities, followed by incrementally increasing amounts that later improves the ability of patient to specific allergen.

The treatment is expected to spread relief to millions of people in the region living with life-threatening peanut allergy. UK agencies are urging for testing of soy product from India because of peanut allergy risk. This is because there has been widespread contamination of the food additive with undeclared peanut protein at different levels over some time, posing a risk to people with peanut allergies. All these factors are expected to drive the Europe Peanut Allergy Market.

Asia Pacific is expected to hold the largest share in the Market despite the allergy is not as prevalent in Western countries. The report states that 0.67 percent in Korean infants, 0.47 to 0.64 percent in Singaporean children, 0.43 percent in Filipino children, 05. To 1.1 percent in Taiwan and almost no cases of peanut allergy in China and Thailand. These are half of the western countries. But the trial conducted in the Australia denotes that children aged six to eighteen have peanut allergies. The Asia Pacific Peanut Allergy Industry growth is supported by the above factors mentioned.

Competitive Landscape

The report provides a detailed data regarding competitive landscape through key players Peanut Allergy Market Size, Peanut Allergy Market Share and Peanut Allergy Market Revenue. The report includes a data about recent developments, Market Penetration, mergers and acquisitions by the major Peanut Allergy Key Companies.

Recently, on May 28, 2020, Aimmune Therapeutics, Inc, a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies announced that findings from APPEAL-1 (Allergy to Peanuts ImPacting Emotions And Life-1), a multi-dimensional pan-European study assessing the psychosocial effect and impact of living with peanut allergy, were published in Allergy, one of the official journals of European Academy of Allergy and Clinical Immunology (EAACI). The study, published in two parts (Part A and Part B), highlights the substantial impact peanut allergy has on every aspect of allergic individuals’ and their caregivers’ lives, including the uncertainty they feel around how to manage frightening and debilitating reactions and concerns about the feasibility of ongoing avoidance.

The organization not only focusing on just physical aspect of the peanut allergy but on social and psychological impact on the humans. This is expected to drive the Market. DBV Technologies, Sanofi, Vedanta Biosciences Inc, Alladapt Immunotherapeutics, Inc., InnoUp and Cambridge Allergy Ltd. are some of the major Peanut Allergy Key Players.

Peanut Allergy Market Segment Analysis

Based on Product Type

The research proved that liquid dosage in the treatment of any allergy have early relief. The liquid dosage segment held the largest revenue share in the Peanut Allergy Market. Liquid dosage are easily digest and started showing results. The ingredients such as adsorbents and antacids deliver more intense effects, when taken in liquid forms. Measurement of different volume can easily and conveniently adjust the dose of the substance. Liquid dosages are in sweetened, colored and flavored forms to deliver bitter and unpleasant medicines. Whereas, solid dosages are difficult to consume and took time to digest in blood to show the results. These factors are expected to boost the liquid dosage segment in Peanut Allergy Market.

Based on End-Use

Hospitals are demanding for the drugs and medicines used in the cure of peanut allergy since the allergic patients mostly visits hospital when symptoms shown due to its life-threatening effects. Hence, the hospital segment held the largest share of the Market. The increased expenditure on healthcare sector across the world and the launch of innovative technologies in the medical field has been driving the segment to grow significantly during the forecast period.

Peanut Allergy Market Scope: Inquire before buying

Peanut Allergy Market, by Region:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan, and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Peanut Allergy Key Players include:

1. DBV Technologies
2. Sanofi
3. Vedanta Biosciences Inc
4. Alladapt Immunotherapeutics, Inc.
5. InnoUp
6. Cambridge Allergy Ltd.
7. COUR Pharmaceuticals
8. Regeneron Pharmaceuticals Inc.
9. Aimmune Therapeutics
10. Moonlight Therapeutics
11. Prota Therapeutics
12. Intrommune Therapeutics
13. Blue Willow Biologics
14. Aravax Pty Ltd.

Frequently Asked Questions:

1] What is the growth rate of the Peanut Allergy Market?
Ans. The Market is growing at a CAGR of 110% during the forecast period.

2] Which region is expected to dominate the Peanut Allergy Market?
Ans. North America is expected to dominate the Peanut Allergy Market during the forecast period from 2024 to 2030.

3] What is the expected Peanut Allergy Market size by 2030?
Ans. The size of the Peanut Allergy Market by 2030 is expected to reach USD 40.84 Bn.

4] Who are the top players in the Market?
Ans. The major key players in the Market are DBV Technologies, Sanofi, Vedanta Biosciences Inc and Alladapt Immunotherapeutics, Inc.

5] Which factors contributed to the growth of the Peanut Allergy Market in 2023?
Ans. The Peanut Allergy Market is expected to grow due to the rising prevalence of peanut allergies across the world.